A Safety, Tolerability, and Pharmacokinetic Study of 1- and 2-mL Injections of LY3074828 Solution Using Investigational Pre-filled Syringes and Investigational Autoinjectors in Healthy Subjects

Trial Profile

A Safety, Tolerability, and Pharmacokinetic Study of 1- and 2-mL Injections of LY3074828 Solution Using Investigational Pre-filled Syringes and Investigational Autoinjectors in Healthy Subjects

Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 18 Jun 2018

At a glance

  • Drugs Mirikizumab (Primary)
  • Indications Crohn's disease; Plaque psoriasis; Ulcerative colitis
  • Focus Adverse reactions; Pharmacokinetics
  • Sponsors Eli Lilly
  • Most Recent Events

    • 08 Jun 2018 Status changed from recruiting to active, no longer recruiting.
    • 28 Mar 2018 Status changed from not yet recruiting to recruiting.
    • 09 Mar 2018 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top